Medindia

X

FDA Grants Orphan Drug Designation to Debiopharm International SA's IAP Inhibitor Debio 1143 in the Treatment of Ovarian Cancer

Thursday, June 2, 2016 Cancer News J E 4
Advertisement

LAUSANNE, Switzerland, June 2, 2016 /PRNewswire/ --

Debiopharm International SA (Debiopharm), a Swiss-based company, part of Debiopharm Group™, today announced that the FDA Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to Debio 1143 for treatment of ovarian cancer.

Orphan Drug Designation by the FDA provides regulatory and financial incentives to develop therapies for life-threatening or chronically debilitating conditions affecting fewer than 200,000 people in the US, or that affect more than 200,000 persons but are not expected to recover the costs of developing and marketing a treatment drug, and for which no satisfactory treatment is available.

Debio 1143 is an oral, small molecule inhibitor of IAPs (Inhibitor of Apoptosis Proteins) with a dual pro-apoptotic and immunomodulatory mode of action developed as a potent chemo/radio-sensitizer in oncology. Further to the encouraging signs of efficacy seen in clinical phase I and supported by this significant regulatory milestone, Debiopharm will soon expand the clinical development of this therapy to patients with ovarian cancer.

"Obtaining orphan designation for Debio 1143 in the United States is an important regulatory milestone", stated Peggy Lipp, Director, Regulatory Affairs, Business Intelligence & Market Access, Debiopharm International S.A. "It speaks to the need for new treatment options in this chronically debilitating and life threatening condition and the potential role of Debio 1143's mode of action. This orphan drug designation is a proof of our commitment to developing innovative therapies for oncology patients."

About Debiopharm International SA 

Debiopharm Group is a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investment management. Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide.

For more information, please visit http://www.debiopharm.com

We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews

Debiopharm International SA Contact Christelle Tur Communication Coordinator christelle.tur@debiopharm.com Tel: +41-(0)21-321-01-11 Additional Media Contacts In London Maitland Chiara Valsangiacomo cvalsangiacomo@maitland.co.uk Tel: +44-(0)20-7379-5151 In New York Russo Partners, LLC Lena Evans Assistant Vice President lena.evans@russopartnersllc.com Tel: +1-212-845-4262

SOURCE Debiopharm Group

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Gastric Cancer Market 2016 Report - Her2 Positive,...
S
Global and China Lensmeter Market 2016-2021 Foreca...